SSY Group Limited announced that the National Medical Products Administration of China has approved the drug supplemental application for Azithromycin for Injection (0.5g and 0.25g) (the "Product") by Shijiazhuang No. 4 Pharmaceutical Co. Ltd. The Product is a type of lyophilized powder for injection, and is mainly used for treatment of a number of infections caused by pathogenic bacteria. Through obtaining lyophilized powder for injection for the first time, the Group accelerates its enterprise transformation.